AI assistant
Sending…
Neurogene Inc. — Director's Dealing 2015
Aug 26, 2015
33497_dirs_2015-08-26_f4083c22-7f8d-4580-bf26-9667003c51c8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2015-08-24
Reporting Person: Mitchell David Chilton (VP Global Regulatory & Quality)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-08-24 | Common Stock | P | 3575 | $17.81 | Acquired | 3575 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1600 | Direct |
More from Neurogene Inc.
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Regulatory Filings
2026
Mar 24
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24